OSTEOPONTIN IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS AS A PREDICTOR OF CARDIOVASCULAR EVENTS
- Authors: Suvorova N.A.1,2, Gordeev I.G.3, Luchinkina E.E.3
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
- O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (on the basis of O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow)
- Issue: Vol 8, No 9 (2022)
- Pages: 53-59
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/276835
- DOI: https://doi.org/10.18565/therapy.2022.9.53-58
- ID: 276835
Cite item
Open Access
Access granted
Abstract
Currently, the problem of finding a predictor of chronic obstructive pulmonary disease (COPD) progression and the development of its complications is extremely actual. One of the markers of systemic inflammation described in the literature is osteopontin (OPN), an elevated level of which is associated with the risk of adverse cardiovascular events' development. The aim of the study is to evaluate the influence of elevated OPN level at the frequency of hospitalizations for COPD exacerbation and the development of cardiovascular events in patients with cardiorespiratory pathology. Material and methods. The study included 99 patients with proven diagnosis of COPD A-D by the GOLD scale, in combination with coronary heart disease (CHD) and without it. In all patients, OPN level was determined, analysis of cardiovascular events and hospitalizations' frequency for COPD exacerbations during 1 year of follow-up was made. Results. OPN has a significant direct correlation with probability of hospitalization development, while the values of this marker ≥ 71,74 ng/ml corresponded to the presence of hospitalization for exacerbation of COPD or a cardiovascular event. Conclusion. Detecting OPN level will let to improve approaches to the tactics of managing COPD patients, identify risk groups, and carry out timely therapy correction.
Full Text
About the authors
Natalya A. Suvorova
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow
Email: natalia-suvorova@inbox.ru
assistant at the Department of hospital therapy named after Academician P.E. Lukomsky of the Faculty of general medicine; general practitioner 111539, Moscow, 23/4 Veshnyakovskaya Str
Ivan G. Gordeev
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (on the basis of O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow)Dr. med. habil., professor; head of the Department of hospital therapy named after Academician P.E. Lukomsky of the Faculty of general medicine 111539, Moscow, 23/4 Veshnyakovskaya Str
Elena E. Luchinkina
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (on the basis of O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow)PhD in Medicine, associate professor of the Department of hospital therapy named after Academician P.E. Lukomsky of the Faculty of general medicine 111539, Moscow, 23/4 Veshnyakovskaya Str
References
- Halpin D.M.G., Celli B.R., Criner G.J. The GOLD Summit on chronic obstructive pulmonary disease in lowand middle-income countries.Int J Tuberc Lung Dis. 2019; 23(11): 1131-41. https://dx.doi.org/10.5588/ijtld.19.0397.www.therapy-journal.ru www.rnmot.ru
- Rabe K.F., Hurst J.R., Suissa S. Cardiovascular disease and COPD: Dangerous liaisons? Eur Respir Rev. 2018; 27(149): 180057. https://dx.doi.org/10.1183/16000617.0057-2018.
- Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Lancet Respir Med. 2015; 3(8): 631-39. https://dx.doi.org/10.1016/S2213-2600d5)00241-6.
- Игнатова ГЛ., Антонов В.Н. Прогностические индексы и маркеры системного воспаления у пациентов с ХОБЛ и ИБС. Медицинский совет. 2017; 4: 81-85. [Ignatova G.L., Antonov V.N. Prognostic indices and markers of systemic inflammation in patients with COPD and CaD. Meditsinskiy sovet = Medical Council. 2017; 4: 81-85 (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2017-4-81-85. EDN: YPTJGL.
- Гайнитдинова В.В., Авдеев С.Н., Неклюдова Г.В. с соавт. Влияние сопутствующих сердечно-сосудистых заболеваний на течение и прогноз хронической обструктивной болезни легких. Пульмонология. 2019; 29(1): 35-42. https://dx.doi.org/10.18093/0869-0189-2019-29-1-19-34. EDN: QKZVAQ.
- Kraen M., Frantz S., Nihlen U. et al. Matrix metalloproteinases in COPD and atherosclerosis with emphasis on the effects of smoking. PLoS One. 2019; 14(2): e0211987. https://dx.doi.org/10.1371/journal.pone.0211987.
- Hawkins N.M., Khosla A., Virani S.A. et al. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med. 2017; 17(1): 11. https://dx.doi.org/10.1186/s12890-016-0345-7.
- Miller J., Edwards L.D., Agusti A. et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013; 107(9): 1376-84. https://dx.doi.org/10.1016/j.rmed.2013.05.001.
- Zhu Z., He Y., Shi M. et al. Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke. Atherosclerosis. 2021; 332: 33-40. https://dx.doi.org/10.1016/j.atherosclerosis.2021.07.010.
- Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014; 236(2): 327-37. https://dx.doi.org/10.1016/j.atherosclerosis.2014.07.004.
- Abdalrhim A.D., Marroush T.S., Austin E.E. et al. Plasma osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. PLoS One. 2016; 11(6): e0156965. https://dx.doi.org/10.1371/journal.pone.0156965.
- Lee S.J., Kim S.H., Kim W. et al. Increased plasma osteopontin in frequent exacerbator and acute exacerbation of COPD. Clin Respir J. 2014; 8(3): 305-11. https://dx.doi.org/10.1111/crj.12072.
- Papaporfyriou A., Loukides S., Kostikas K. et al. Increased levels of osteopontin in sputum supernatant in patients with COPD. Chest. 2014; 146(4): 951-58. https://dx.doi.org/10.1378/chest.13-2440.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2021. URL: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf (date of access - 01.11.2022).
- Westerik J.A., Metting E.I., van Boven J.F. et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017; 18(1): 31. https://dx.doi.org/10.1186/s12931-017-0512-2.
- Keene J.D., Jacobson S., Kechris K. et al; COPDGene and SPIROMICS Investigators. Biomarkers predictive of exacerbations in the SPIROMIcS and COPDGene cohorts. Am J Respir Crit Care Med. 2017; 195(4): 473-81. https://dx.doi.org/10.1164/rccm.201607-1330OC.
Supplementary files
